Claims for Patent: 10,307,379

Summary for Patent: 10,307,379

Title:	Donepezil transdermal delivery system
Abstract:	A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.
Inventor(s):	Lee; Eun Soo (Redwood City, CA), Jain; Amit K. (Milpitas, CA), Singh; Parminder (Union City, CA)
Assignee:	Corium, Inc. (Menlo Park, CA)
Application Number:	15/957,858
Patent Claims:	1. A composition, comprising: a drug reservoir comprised of a molar amount of donepezil HCl, an equimolar or less than equimolar amount of a pharmaceutically acceptable alkaline salt, a solvent composition comprising a hydrophilic solvent, and an acrylate copolymer, wherein the alkaline salt is sodium bicarbonate or potassium bicarbonate; and a skin contact adhesive comprising one or more of (i) triethyl citrate, (ii) sorbitan monolaurate, and (iii) lauryl lactate, wherein reaction of donepezil HCl and the alkaline salt generates a therapeutically effective amount of donepezil base in situ in the drug reservoir when the skin contact adhesive is attached to skin of a subject. 2. The composition of claim 1, wherein the solvent composition comprises one or more of triethyl citrate, sorbitan monolaurate, and lauryl lactate. 3. The composition of claim 1, wherein the solvent composition comprises between about 8-12 wt % triethyl citrate, between about 1.5-2.5 wt % sorbitan monolaurate, and between about 1-10 wt % lauryl lactate. 4. The composition of claim 3, wherein the skin contact adhesive comprises between about 1-20 wt % triethyl citrate, between about 0.01-5 wt % sorbitan monoloaurate, and between about 0.1-10 wt % lauryl lactate. 5. The composition of claim 1, wherein the hydrophilic solvent is selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, acetonitrile, 1-propanol, and N,N-dimethylformamide. 6. The composition of claim 1, wherein the hydrophilic solvent is glycerin. 7. The composition of claim 6, comprising between about 5-15 wt % glycerin. 8. The composition of claim 1, comprising between about 1-5 wt % sodium bicarbonate. 9. The composition of claim 1, comprising between about 5-25 wt % donepezil HCl. 10. A composition, comprising: a drug reservoir comprised of a molar amount of a donepezil salt, an equivalent or less than equivalent amount of a pharmaceutically acceptable alkaline salt, a solvent composition comprising a hydrophilic solvent, and an acrylate copolymer, wherein the alkaline salt is sodium bicarbonate or potassium bicarbonate; and a skin contact adhesive comprising one or more of (i) triethyl citrate, (ii) sorbitan monolaurate, and (iii) lauryl lactate, wherein reaction of the donepezil salt and the alkaline salt generates a therapeutically effective amount of donepezil base in situ in the drug reservoir when the skin contact adhesive is attached to skin of a subject. 11. The composition of claim 10, wherein the solvent composition comprises between about 8-12 wt % triethyl citrate, between about 1.5-2.5 wt % sorbitan monolaurate, and between about 1-10 wt % lauryl lactate. 12. The composition of claim 11, wherein the skin contact adhesive comprises between about 1-20 wt % triethyl citrate, between about 0.01-5 wt % sorbitan monoloaurate, and between about 0.1-10 wt % lauryl lactate. 13. The composition of claim 10, wherein the hydrophilic solvent is selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, acetonitrile, 1-propanol, and N,N-dimethylformamide. 14. The composition of claim 10, wherein the hydrophilic solvent is glycerin. 15. The composition of claim 14, comprising between about 5-15 wt % glycerin. 16. The composition of claim 10, comprising between about 1-5 wt % sodium bicarbonate. 17. The composition of claim 10, wherein the donepezil salt is donepezil HCl. 18. The composition of claim 17, comprising between about 5-25 wt % donepezil HCl.